Page 24 - வைத்திருத்தல் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SUZHOU, China, April 20, 2021 /PRNewswire/ Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of its IND for TST005 from US FDA for initiating Phase I clinical trial of its bi-functional anti-PD-L1/TGF-β antibody. TST005, is a bi-functional anti-PD-L1 and TGF-β trap fusion protein designed to simultaneously target two immuno-suppressive pathways, transforming growth factor -β (TGF-β) and programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. TST005 consists of a high affinity PD-L1 antibody fused with an engineered TGF-β Receptor Type II protein in its C-terminal. TST005 lacks FcR binding activity and thus has reduced FcR mediated killing of PD-L1 expressing effector T cells. TST005 s high P

United statesMichael shiPrnewswire transcenta holding limitedClinical development centersTranscenta holdingProduct development centerTranslational research centerHolding limitedReceptor typeManufacturing facilityExternal partnering centerஒன்றுபட்டது மாநிலங்களில்மைக்கேல் ஷிமருத்துவ வளர்ச்சி மையங்கள்ப்ராடக்ட் வளர்ச்சி மையம்மொழிபெயர்ப்பு ஆராய்ச்சி மையம்